SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
CFO is getting paid $400,000 per year! This is crazy at the current position the company is in...
Is MACK overvalued at current levels? Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awesom_sto-cks.
Are the rumors of mack stock doing a reverse split reverse splits are going good there any rumors of it can anybody tell me anything good about the stock I'm curious is it worth buying thank you
Debt free is good enough for me !
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 14 cents per share.
The company's shares closed at $1.30. A year ago, they were trading at $5.26.
_____The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 14 cents per share.
The company's shares closed at $1.30. A year ago, they were trading at $5.26.
Anybody ever day trade any stocks and actually make money what are the name of a couple stock anybody trades and make money over and over
Is mark going to do a reverse split?
HOW TO GET YOUR EX LOVER BACK. I want to share my testimony with everyone, my name is Victoria Desmond from USA, after 4 years of marriage with my husband ,he left me for another woman which led me into frustration. I did all i could to get him back but none availed, until an old friend of mine told me about a spell caster Dr.jaja on the internet who helped her in a similar problem, at first i doubted it but I decided to give it a try.I contacted the doctor (firstname.lastname@example.org) he helped me cast a spell on my husband and within 48 hours my husband came back home to me again. I can't stop giving thanks to JAJA . Contact this great spell caster on any of your problems, he is capable of providing a lasting solution to all your problems: (1) Breakup and Love Spells (2) Bring back your Ex or lost love (3) Stop divorce or divorce spell (4) Marriage Spells (5) Pregnancy and Child bearing spell (6) Business Spell (7) Remove sickness from your body spell (8) you want women/men to run after you (9) Lottery winning numbers 10) you want to be rich and famous 11) You want to be promoted in your office Contact this great man via: email@example.com
For all those who think it is a good idea to reverse split a stock, play with the following formulas:
Share price X no shares = value $100 / no shares = $100 price change split involves current shares X current price = new shares X new price 2:1 split is new (2 x shares X price / 2) = old (1 x shares X price /1) new $100 price change = $100 / (2 x shares) e.g old $100/1000 = $0.1 new $100/2000 = $0.05 1:2 split is new (shares / 2 X 2 x price) = old (1 x shares X price /1) new $100 price change = $100 / (shares / 2) e.g. old $100 / 1000 = $0.1 new $100 / 500 = $0.2
As far as a 10:1 split, I would prefer my current $100 price change of $0.05 to the 10:1 split $100 price change of $0.50 Currently if the price would increase by $0.50, I would recover $1000 of my loss.
The company's shares closed at $1.30. A year ago, they were trading at $5.26. Enough said.
0.40 / share payment coming next month.
I see great things happening with MACK as they restructure their management and ready their products for market. Look forward to all these changes to pay off, and they will give it time. Merrimack is a great company with great innovation.
Does anyone know if its a good idea to vote for the reverse stock split on Mack ???
Got a great report from http://thewolftrader.com/?s=MACK about $MACK. I did have to subscribe but it was worth the time. Thank you guys for the tip! Making money day trading. "rht"
The Wolf Trader: Trading Stocks and Making Money
Stock alerts from the The Wolf Trader. Stock trading, making money and always looking for the next big money maker.
Does anyone know when MACK reports their earnings? August 2nd?
KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys
Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
“KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”
Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.
I'm with Mack till the end. Come on calls make me some money
MicroCap Alert to MACK shareholders. Why Clean Energy Technologies (CETY) shares moved up recently and why they are about to rise sharply again. CETY purchased their Heat Recovery Systems from General Electric. Each system sells for about $300,000. Demand for CETY HRS is very strong. CETY just expanded Europe sales and service office in high demand market CETY immediately announced first new sale in Europe CETY presenting to 26 Power Companies in the Pacific on July 31st to August 4th – These 26 power companies need CETY HRS to produce power cheaper and make more profits.
Expect substantial sales orders to flow soon after conference CETY 1017 target: $.15 to $.20